Atrial Fibrillation (A-FIB)

Categories: Blood diseases, Cardiovascular diseases, Genetic diseases, Mental diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Atrial Fibrillation

MalaCards integrated aliases for Atrial Fibrillation:

Name: Atrial Fibrillation 12 36 29 54 6 42 3 44 15 62 62 17 71
Fibrillation, Atrial 39
a-Fib 12


External Ids:

Disease Ontology 12 DOID:0060224
KEGG 36 H00731
ICD9CM 34 427.31
MeSH 44 D001281
NCIt 50 C50466
SNOMED-CT 67 266306001
UMLS 71 C0004238

Summaries for Atrial Fibrillation

PubMed Health : 62 About atrial fibrillation: Atrial fibrillation (A-tre-al fi-bri-LA-shun), or AF, is the most common type of arrhythmia (ah-RITH-me-ah). An arrhythmia is a problem with the rate or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. AF occurs if rapid, disorganized electrical signals cause the heart's two upper chambers—called the atria (AY-tree-uh)—to fibrillate. The term "fibrillate" means to contract very fast and irregularly. In AF, blood pools in the atria. It isn't pumped completely into the heart's two lower chambers, called the ventricles (VEN-trih-kuls). As a result, the heart's upper and lower chambers don't work together as they should. People who have AF may not feel symptoms. However, even when AF isn't noticed, it can increase the risk of stroke. In some people, AF can cause chest pain or heart failure, especially if the heart rhythm is very rapid. AF may happen rarely or every now and then, or it may become an ongoing or long-term heart problem that lasts for years.

MalaCards based summary : Atrial Fibrillation, also known as fibrillation, atrial, is related to congestive heart failure and long qt syndrome 10, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Atrial Fibrillation is SCN5A (Sodium Voltage-Gated Channel Alpha Subunit 5), and among its related pathways/superpathways are Vascular smooth muscle contraction and Adrenergic signaling in cardiomyocytes. The drugs Ranolazine and Hydroxychloroquine have been mentioned in the context of this disorder. Affiliated tissues include heart, kidney and brain, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A heart conduction disease that is characterized by uncoordinated electrical activity in the heart's upper chambers (the atria), which causes the heartbeat to become fast and irregular and has symptoms palpitations, weakness, fatigue, lightheadedness, dizziness, confusion, shortness of breath and chest pain.

MedlinePlus : 42 An arrhythmia is a problem with the speed or rhythm of the heartbeat. Atrial fibrillation (AF) is the most common type of arrhythmia. The cause is a disorder in the heart's electrical system. Often, people who have AF may not even feel symptoms. But you may feel Palpitations -- an abnormal rapid heartbeat Shortness of breath Weakness or difficulty exercising Chest pain Dizziness or fainting Fatigue Confusion AF can lead to an increased risk of stroke. In many patients, it can also cause chest pain, heart attack, or heart failure. Doctors diagnose AF using family and medical history, a physical exam, and a test called an electrocardiogram (EKG), which looks at the electrical waves your heart makes. Treatments include medicines and procedures to restore normal rhythm. NIH: National Heart, Lung, and Blood Institute

CDC : 3 Atrial fibrillation, often called AFib or AF, is the most common type of heart arrhythmia. An arrhythmia is when the heart beats too slowly, too fast, or in an irregular way. When a person has AFib, the normal beating in the upper chambers of the heart (the two atria) is irregular, and blood doesn't flow as well as it should from the atria to the lower chambers of the heart (the two ventricles). AFib may occur in brief episodes, or it may be a permanent condition.

KEGG : 36 Atrial fibrillation (AF, ATFB) is the most common cardiac arrhythmia and is regarded generally as a sporadic, acquired disorder. Nevertheless, recent growing evidence points to an important heritable basis for AF. By linkage analysis, several loci have been mapped for monogenetic AF. Some of these loci encode for subunits of potassium channels.

Wikipedia : 74 Atrial fibrillation (AF or A-fib) is an abnormal heart rhythm (arrhythmia) characterized by the rapid... more...

Related Diseases for Atrial Fibrillation

Diseases in the Atrial Fibrillation family:

Atrial Fibrillation, Familial, 3 Atrial Fibrillation, Familial, 1
Atrial Fibrillation, Familial, 2 Atrial Fibrillation, Familial, 4
Atrial Fibrillation, Familial, 5 Atrial Fibrillation, Familial, 6
Atrial Fibrillation, Familial, 7 Atrial Fibrillation, Familial, 8
Atrial Fibrillation, Familial, 9 Atrial Fibrillation, Familial, 10
Atrial Fibrillation, Familial, 11 Atrial Fibrillation, Familial, 12
Atrial Fibrillation, Familial, 13 Atrial Fibrillation, Familial, 14
Atrial Fibrillation, Familial, 15 Atrial Fibrillation, Familial, 18
Familial Atrial Fibrillation

Diseases related to Atrial Fibrillation via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 908)
# Related Disease Score Top Affiliating Genes
1 congestive heart failure 32.7 SCN5A NPPB NPPA KCNQ1
2 long qt syndrome 10 32.5 SNTA1 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
3 familial sick sinus syndrome 32.2 SCN5A HCN4
4 short qt syndrome 32.2 SCN5A KCNQ1 KCNJ2 KCNH2 KCNE2
5 cardiac arrhythmia 32.2 SCN5A SCN3B SCN1B KCNQ1 KCNH2 KCNE2
6 atrial standstill 1 32.1 SCN5A SCN1B NPPB GJA5 ABCC9
7 wolff-parkinson-white syndrome 32.1 SCN5A NPPB KCNQ1 ABCC9
8 syncope 32.0 SCN5A NPPA KCNQ1 KCNH2
9 ventricular fibrillation, paroxysmal familial, 1 32.0 SCN5A KCNQ1 KCNH2 KCNE2
10 familial atrial fibrillation 32.0 SNTA1 SCN5A SCN4B SCN3B SCN2B SCN1B
11 myocardial infarction 31.9 SCN5A NPPB NPPA MYL4 KCNQ1 ABCC9
12 atrioventricular block 31.9 SCN5A NPPB KCNQ1 KCNH2 KCNE2 HCN4
13 sick sinus syndrome 31.9 SNTA1 SCN5A SCN3B SCN1B NPPA HCN4
14 heart disease 31.8 ZFHX3 SCN5A NPPB NPPA MYL4 KCNQ1
15 atrial heart septal defect 31.8 SCN5A NPPB NPPA GJA5
16 progressive familial heart block, type ia 31.8 SCN5A GJA5 ANK2
17 cardiac conduction defect 31.8 SCN5A SCN1B KCNQ1 KCNH2 HCN4
18 cardiac arrhythmia, ankyrin-b-related 31.6 SNTA1 SCN5A SCN4B KCNQ1 KCNJ2 KCNH2
19 patent foramen ovale 31.6 NPPB NPPA GJA5
20 lipoprotein quantitative trait locus 31.5 ZFHX3 SCN5A NPPB NPPA KCNQ1 KCNJ2
21 cardiac arrest 31.5 SCN5A NPPB KCNQ1 KCNH2 ANK2
22 left bundle branch hemiblock 31.5 SCN5A NPPB
23 hypertrophic cardiomyopathy 31.4 SCN5A NPPB NPPA KCNQ1 KCNJ2 KCNH2
24 sinoatrial node disease 31.4 SCN5A SCN3B SCN1B KCNQ1 KCNJ2 KCNH2
25 aortic valve disease 2 31.2 NPPB NPPA MYL4
26 right bundle branch block 31.1 SCN5A SCN3B SCN2B SCN1B NPPB KCNH2
27 atrial standstill 31.1 SCN5A NPPA GJA5
28 first-degree atrioventricular block 31.0 SCN5A NPPB KCNJ2 KCNH2
29 second-degree atrioventricular block 31.0 SCN5A SCN3B HCN4
30 tetralogy of fallot 30.8 SCN5A NPPB NPPA KCNH2 GJA5
31 third-degree atrioventricular block 30.8 SCN5A SCN1B NPPB KCNJ2 KCNH2 HCN4
32 familial short qt syndrome 30.7 KCNQ1 KCNJ2 KCNH2
33 dilated cardiomyopathy 30.7 SNTA1 SCN5A SCN4B SCN2B NPPB NPPA
34 arrhythmogenic right ventricular cardiomyopathy 30.7 SCN5A NPPB KCNH2 HCN4 ANK2 ABCC9
35 anterolateral myocardial infarction 30.4 NPPB NPPA
36 ebstein anomaly 30.4 SCN5A HCN4 GJA5
37 brugada syndrome 1 30.3 SCN5A KCNH2 KCNA5
38 long qt syndrome 30.3 SNTA1 SCN5A SCN4B SCN3B SCN2B SCN1B
39 brugada syndrome 30.2 SNTA1 SCN5A SCN4B SCN3B SCN2B SCN1B
40 familial long qt syndrome 30.2 SNTA1 SCN5A SCN4B KCNQ1 KCNH2 KCNE2
41 left ventricular noncompaction 30.2 SNTA1 SCN5A SCN3B SCN2B SCN1B KCNQ1
42 progressive familial heart block 30.1 SCN5A SCN1B KCNQ1 KCNH2 HCN4 GJA5
43 catecholaminergic polymorphic ventricular tachycardia 29.9 SNTA1 SCN5A SCN4B SCN3B SCN1B KCNQ1
44 long qt syndrome 3 29.8 SNTA1 SCN5A SCN4B SCN3B SCN1B KCNQ1
45 sudden infant death syndrome 29.7 SNTA1 SCN5A SCN4B SCN3B SCN2B SCN1B
46 long qt syndrome 5 29.6 SNTA1 SCN5A SCN4B KCNQ1 KCNJ2 KCNH2
47 timothy syndrome 29.6 SNTA1 SCN5A SCN4B KCNQ1 KCNJ2 KCNH2
48 jervell and lange-nielsen syndrome 1 29.6 SNTA1 SCN5A SCN4B KCNQ1 KCNJ2 KCNH2
49 andersen cardiodysrhythmic periodic paralysis 29.6 SNTA1 SCN5A SCN4B KCNQ1 KCNJ2 KCNH2
50 long qt syndrome 1 29.5 SNTA1 SCN5A SCN4B SCN3B SCN2B SCN1B

Graphical network of the top 20 diseases related to Atrial Fibrillation:

Diseases related to Atrial Fibrillation

Symptoms & Phenotypes for Atrial Fibrillation

UMLS symptoms related to Atrial Fibrillation:

angina pectoris, chest pain, edema

GenomeRNAi Phenotypes related to Atrial Fibrillation according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00240-S-1 9.55 MYL4
2 Decreased viability GR00249-S 9.55 ABCC9 GJA5 KCNE2 MYL4 NPPA SCN1B
3 Decreased viability GR00402-S-2 9.55 KCNE2 KCNJ2 KCNQ1 NPPA NUP155 SCN1B

MGI Mouse Phenotypes related to Atrial Fibrillation:

# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.03 ABCC9 GJA5 HCN4 KCNA5 KCNH2 KCNJ2
2 homeostasis/metabolism MP:0005376 10 ABCC9 GJA5 KCNA5 KCNE2 KCNH2 KCNJ2
3 muscle MP:0005369 9.7 ABCC9 GJA5 HCN4 KCNA5 KCNH2 KCNJ2
4 nervous system MP:0003631 9.36 ABCC9 HCN4 KCNA5 KCNQ1 NUP155 SCN1B

Drugs & Therapeutics for Atrial Fibrillation

PubMed Health treatment related to Atrial Fibrillation: 62

Treatment for atrial fibrillation (AF) depends on how often you have symptoms, how severe they are, and whether you already have heart disease . General treatment options include medicines, medical procedures, and lifestyle changes.

Drugs for Atrial Fibrillation (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 374)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Ranolazine Approved, Investigational Phase 4 95635-55-5, 142387-99-3 56959
Hydroxychloroquine Approved Phase 4 118-42-3 3652
carbamide peroxide Approved Phase 4 124-43-6
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
5 fluindione Approved, Investigational Phase 4 957-56-2
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
Terazosin Approved Phase 4 63590-64-7 5401
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
Antazoline Approved Phase 4 91-75-8 2200
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
Nifedipine Approved Phase 4 21829-25-4 4485
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
Ezetimibe Approved Phase 4 163222-33-1 150311
19 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
Pantoprazole Approved Phase 4 102625-70-7 4679
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
Amlodipine Approved Phase 4 88150-42-9 2162
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
Atorvastatin Approved Phase 4 134523-00-5 60823
Ticlopidine Approved Phase 4 55142-85-3 5472
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
Liraglutide Approved Phase 4 204656-20-2 44147092
Methohexital Approved Phase 4 151-83-7 9034
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560
Ketoconazole Approved, Investigational Phase 4 65277-42-1 47576
Metoprolol Approved, Investigational Phase 4 51384-51-1, 37350-58-6 4171
Enoxaparin Approved Phase 4 9005-49-6 772
Verapamil Approved Phase 4 52-53-9 2520
Ticagrelor Approved Phase 4 274693-27-5 9871419
Procainamide Approved Phase 4 51-06-9 4913
Digoxin Approved Phase 4 20830-75-5 30322 2724385
Diltiazem Approved, Investigational Phase 4 42399-41-7 39186
Racepinephrine Approved Phase 4 329-65-7 838
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
Empagliflozin Approved Phase 4 864070-44-0
Esmolol Approved Phase 4 81147-92-4, 103598-03-4 59768
Bivalirudin Approved, Investigational Phase 4 128270-60-0 16129704
Ropivacaine Approved Phase 4 84057-95-4 71273 175805

Interventional clinical trials:

(show top 50) (show all 2543)
# Name Status NCT ID Phase Drugs
1 SILENT - Subclinical AtrIal FibrilLation and StrokE PreveNtion Trial Unknown status NCT02004509 Phase 4 anticoagulant by physician criteria
2 Randomized Controlled Trial to Evaluate Implanted Event Recorders for the First Diagnosis of Atrial Fibrillation in High-risk Patients Unknown status NCT01461434 Phase 4
3 PV-Isolation for Paroxysmal Atrial Fibrillation: Isolation of the Arrhythmogenic Vein(s) vs. Isolation of All Veins Unknown status NCT00605748 Phase 4
4 Test of Efficacy and Safety of the Dual Antiplatelet Therapy Compared to the Combination of Oral Anticoagulant Therapy + Dual Antiplatelet Therapy in Patients With Atrial Fibrillation With Low-moderate Risk Submitted to Coronary Stent Implantation Unknown status NCT01141153 Phase 4 Acetylsalicylic Acid + clopidogrel + acenocoumarol;Acetylsalicylic Acid + clopidogrel
5 The Early Diagnosis and Prevention of Ischemic Stroke and Cognition Decline Associated With Coronary Artery Disease Combined With Cerebral Artery Stenosis or Arrhythmia by 24-Hour Simultaneous Recorder of Electrocardiograph and Electroencephalography Unknown status NCT00247533 Phase 4
6 Randomized Study Comparing Cardioversion vs. Catheter Ablation in Patients With Persistent Atrial Fibrillation Unknown status NCT00196209 Phase 4
7 Atrial Fibrillation Ablation Compared to Rate Control Strategy in Patients With Recently Diagnosed Impaired Left Ventricular Function: a Multicenter, Randomized Controlled Trial Unknown status NCT02509754 Phase 4
8 Safety and Efficacy of Transvenous Pulmonary Isolation for the Treatment of Atrial Fibrillation: A Prospective Randomized Study Comparing Radiofrequency Energy With Cryoenergy Unknown status NCT00773539 Phase 4
9 Comparison of Efficacy and Safety Among DAbigatran, RIvaroxaban, and ApixabaN in Patients HavinG Non-Valvular Atrial Fibrillation in Taiwan (DARING-AF Study) Unknown status NCT02666157 Phase 4 Dabigatran etexilate;Rivaroxaban;Apixaban
10 A Prospective Study of Medical Therapy Against Cryoballoon Ablation in Symptomatic Recent Onset Persistent Atrial Fibrilation Unknown status NCT02389218 Phase 4 sequential drug adjustment (propafenone, sotalol or flecainide)
11 Comparison of Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran in Patients With Non-valvular Atrial Fibrillation (RIVAL-AF Study) -Multicenter Randomized Study- Unknown status NCT02331602 Phase 4 Rivaroxaban;Dabigatran
12 Improving Stroke Prevention in Atrial Fibrillation Through Pharmacist Prescribing: Program for the Identification of 'Actionable' AF (PIAAF) Rx Study Unknown status NCT03126214 Phase 4 Anticoagulants
13 Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients Unknown status NCT01610141 Phase 4
14 Linear Anatomically Versus Focal Electrophysiologically Guided Substrate Ablation in Patients With Persistent Atrial Fibrillation Unknown status NCT00196157 Phase 4
15 Cryoballoon Pulmonary Vein Isolation and Associated Esophageal Effects Unknown status NCT02998866 Phase 4
16 Atrial Fibrillation and Pericardial Drainage: Incidence of Postoperative Atrial Fibrillation According to the Type of Mediastinal Drainage Catheters Unknown status NCT02808897 Phase 4
17 Effect of Hydroxychloroquine on Atrial Fibrillation Recurrence After Radiofrequency Catheter Ablation in Patients With Atrial Fibrillation Unknown status NCT03592823 Phase 4 Hydroxychloroquine Sulfate 200 Mg Tablet
18 Comparison of a Rhythm Control Treatment Strategy Versus a Rate Control Strategy in Patients With Permanent or Long-term Persistent Atrial Fibrillation and Heart Failure Treated With Cardiac Resynchronization Therapy - a Pilot Study Unknown status NCT01850277 Phase 4 Amiodarone;Pharmacotherapy to slow and control ventricular rate
19 The Study of Rosuvastatin for Reduction of Postoperative Paroxysmal Atrial Fibrillation in Patient Undergoing Radiofrequency Catheter Ablation Unknown status NCT02502110 Phase 4 rosuvastatin
20 Effects of Vernakalant and Flecainide on Atrial Contractility in Patients With Atrial Fibrillation Unknown status NCT01646281 Phase 4 Vernakalant;Flecainide
21 Left Atrial Ablation for Paroxysmal Atrial Fibrillation and Hypertension With Implantable Loop Recorder With or Without ROX Coupler Follow Up Study: The LAAPITUP 3 Study Unknown status NCT02243891 Phase 4
22 Impact of Irbesartan on Oxidative Stress and C-Reactive Protein Levels in Patients With Persistent Atrial Fibrillation Unknown status NCT00613496 Phase 4 irbesartan;placebo
23 A Randomized Study Comparing Dabigatran Etexilate Versus Warfarin in Chinese Patients With Nonvalvular Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention With Stenting (DES) Unknown status NCT03536611 Phase 4 dabigatran;warfarin
24 Clinical Efficacy of Potassium Canrenoate - Canrenone in Sinus Rhythm Restoration Among Patients With Atrial Fibrillation and Elevated Blood Pressure - a Pilot Randomized Controlled Trial. Unknown status NCT03536806 Phase 4 Saline 0.9%;Canrenone
25 Intensive Statin Therapy Effect on Incidence of Post-Operative Atrial Fibrillation Unknown status NCT02029534 Phase 4 Atorvastatin 20 mg;Atorvastatin 80 mg
26 Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation Unknown status NCT00224341 Phase 4
27 Dronedarone in Pacemaker Patients With Paroxysmal Atrial Fibrillation Unknown status NCT01070667 Phase 4 Dronedarone;Placebo
28 Randomized Trial Comparing Diltiazem and Metoprolol For Atrial Fibrillation Rate Control Unknown status NCT02025465 Phase 4 Metoprolol;Diltiazem
29 A Randomized, Prospective Multicenter Pilot Study to Determine the Influence of the Ventricular Pacing Site on the Incidence of Atrial Fibrillation and Heart Failure in Patients With Indication for Permanent Pacemaker Stimulation Therapy. Unknown status NCT00292383 Phase 4
30 A Randomized, Prospective Multicenter Study to Determine the Incidence of Atrial Fibrillation and Heart Failure in Correlation to Stimulation Modes of Pacemakers Unknown status NCT00161551 Phase 4
31 The Efficacy and Safety of Dabigatran Etexilate and Different Intensity Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation Unknown status NCT02646267 Phase 4 standard intensity warfarin;low intensity warfarin;dabigatran etexilate
32 Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study (AFIRE Study) Unknown status NCT02642419 Phase 4 Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel);Rivaroxaban
33 A Nationwide Multicenter Trial Assessing the Effects of Catheter Ablation on Burden of Atrial Fibrillation Recorded by Implantable Cardiac Monitor Unknown status NCT02639793 Phase 4
34 Additional Linear Ablation Perpendicular to the Pulmonary Vein Isolation Line Reduces the Recurrence Rate of Paroxysmal Atrial Fibrillation (ALA-PAF) Unknown status NCT02637453 Phase 4
35 Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer: A Controlled, Randomized, Double Blinded Trial Unknown status NCT00724581 Phase 4 Amiodarone
36 N-3 Fatty Acids for the Prevention of Atrial Fibrillation in Patients With Acute Heart Failure Unknown status NCT00692718 Phase 4 Epadel, Eicosapentaenoic acid
37 Atrial Fibrillation Therapy: A Multi-Center Clinical Study Unknown status NCT01341353 Phase 4 Digaoxin,amiodarone,β receptor antagonist, Calcium Antagonists
38 Phenprocoumon Versus Dabigatran in Subjects With Atrial Fibrillation and Left Atrial Thrombus - a Prospective, Randomized, Controlled, Open-label One Year Follow-up Pilot Study Unknown status NCT02591225 Phase 4 Dabigatranetexilate;Phenprocoumon
39 A Prospective, Multi-Center, Pilot Study to Compare the Safety and Effectiveness of WATCHMAN Left Atrial Appendage Occlusion Device With Rivaroxaban for Stroke Prevention in Patients With Atrial Fibrillation Unknown status NCT02549963 Phase 4 Rivaroxaban
40 Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation Unknown status NCT02145546 Phase 4 Amiodarone;Propafenone;Sotalol
41 Improved Exercise Tolerance in Participants With PReserved Ejection Fraction by Spironolactone on Myocardial Fibrosis in Atrial Fibrillation Unknown status NCT02673463 Phase 4 Spironolactone;Placebo
42 Rivaroxaban Once Daily Versus Dose-adjusted Vitamin K Antagonist on the Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF) Unknown status NCT03490994 Phase 4 Rivaroxaban;Warfarin + LMWH
43 Catheter Ablation for Atrial Fibrillation: A Multicenter Clinical Trial Unknown status NCT01113294 Phase 4
44 Left Atrial Ablation of Paroxysmal Atrial Fibrillation With Implantable Loop Recorder Follow Up Study 2 Unknown status NCT01504451 Phase 4
45 Comparison of Efficacy and Safety of Different Doses of Nifekalant Instant Cardioversion of Persistent Atrial Fibrillation During Radiofrequency Ablation:a Single-center Randomized Controlled Trial Unknown status NCT04209959 Phase 4 nifekalant
46 Rate Control in Atrial Fibrillation: A Randomized, Double-Blind, Crossover Comparison of Carvedilol and Metoprolol Tartrate Unknown status NCT02251509 Phase 4 Carvedilol;Metoprolol tartrate
47 The Use of Dabigatran Etexilate in Patients With Atrial Fibrillation After Mitral Valve Prosthetic Replacement Unknown status NCT03183843 Phase 4 Dabigatran Etexilate;Warfarin
48 Pulmonary Vein Isolation With Versus Without Continued Antiarrhythmic Drug Treatment in Subjects With Recurrent Atrial Fibrillation: A Prospective 2-Centre Randomized Controlled Clinical Study (POWDER-AF) Unknown status NCT02475642 Phase 4
49 Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention Unknown status NCT02334254 Phase 4 rivaroxaban and ticagrel therapy;triple antithrombotic regimen with warfarin, asipirin and clopidogrel
50 Safety of Ticagrelor Plus Warfarin Versus Clopidogrel+Aspirin+Warfarin in Patients With Persistent or Permanent Atrial Fibrillation and Undergoing PCI-S: A Randomized, Open, Controlled, Parallel Group, Multi-center Trial Unknown status NCT02206815 Phase 4 Ticagrelor+Warfarin;Clopidogrel+Aspirin+Warfarin

Search NIH Clinical Center for Atrial Fibrillation

Inferred drug relations via UMLS 71 / NDF-RT 51 :

Digitalis preparation
Diltiazem Hydrochloride
Diltiazem maleate
Disopyramide Phosphate
ibutilide fumarate
metoprolol succinate
Metoprolol Tartrate
Procainamide Hydrochloride
Propafenone Hydrochloride
quinidine gluconate
quinidine polygalacturonate
Quinidine Sulfate
Sotalol Hydrochloride
Verapamil hydrochloride
Warfarin Sodium

Cochrane evidence based reviews: atrial fibrillation

Genetic Tests for Atrial Fibrillation

Genetic tests related to Atrial Fibrillation:

# Genetic test Affiliating Genes
1 Atrial Fibrillation 29

Anatomical Context for Atrial Fibrillation

MalaCards organs/tissues related to Atrial Fibrillation:

Heart, Kidney, Brain, Endothelial, Liver, Thyroid, Atrioventricular Node

Publications for Atrial Fibrillation

Articles related to Atrial Fibrillation:

(show top 50) (show all 30630)
# Title Authors PMID Year
How transforming growth factor contributes to atrial fibrillation? 42 61
33309721 2021
33454696 2020
Percutaneous left atrial appendage closure. 42
33380146 2020
Evidence that D-dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy. 54 61
20466203 2010
Predictive value of B-type natriuretic peptide for postoperative atrial fibrillation following pulmonary resection for lung cancer. 54 61
19896864 2010
Association of ADRB1 gene polymorphism with atrial fibrillation. 54 61
20384459 2010
Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation. 61 54
20170814 2010
Brain natriuretic peptide as a predictor of delayed atrial fibrillation after ischaemic stroke and transient ischaemic attack. 61 54
19845751 2010
Increased expression of mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase type 2 in human atria during atrial fibrillation. 61 54
20063294 2010
[Role of ACE-inhibitors in preventing atrial fibrillation relapses in normotensive patients]. 54 61
20066882 2009
Genetic polymorphism of KCNH2 confers predisposition of acquired atrial fibrillation in Chinese. 54 61
19490382 2009
[Associations of the genetic polymorphisms in CYP11B2 gene with nonfamilial structural atrial fibrillation]. 61 54
20193392 2009
Activating autoantibodies to the beta-1 adrenergic and m2 muscarinic receptors facilitate atrial fibrillation in patients with Graves' hyperthyroidism. 54 61
19778674 2009
Interactions of MinK and e-NOS gene polymorphisms appear to be inconsistent predictors of atrial fibrillation propensity, but long alleles of ESR1 promoter TA repeat may be a promising marker. 61 54
19860128 2009
Utility of brain natriuretic peptide as a predictor of atrial fibrillation after cardiac operations. 54 61
19699901 2009
Heart failure may be associated with the onset of ischemic stroke with atrial fibrillation: a brain natriuretic peptide study. 61 54
19321180 2009
Comprehensive mutation scanning of LMNA in 268 patients with lone atrial fibrillation. 61 54
19427440 2009
Effect of Angiotensin converting enzyme inhibitors and Angiotensin receptor blockers on patients following ablation of atrial fibrillation. 54 61
19949577 2009
Changes in plasma von Willebrand factor and ADAMTS13 levels associated with left atrial remodeling in atrial fibrillation. 61 54
18996572 2009
Study of the factors related to atrial fibrillation after coronary artery bypass grafting: a search for a marker to predict the occurrence of atrial fibrillation before surgical intervention. 54 61
19327514 2009
Does treatment of hypertension decrease the incidence of atrial fibrillation and cardioembolic stroke? 61 54
19327599 2009
Gain-of-function mutation of Nav1.5 in atrial fibrillation enhances cellular excitability and lowers the threshold for action potential firing. 61 54
19167345 2009
Candesartan, NT-proBNP and recurrence of atrial fibrillation after electrical cardioversion. 61 54
18201783 2009
Letter by Hong et al regarding article, "Cardiac sodium channel (SCN5A) variants associated with atrial fibrillation". 54 61
18852373 2008
The predictive value of plasma brain natriuretic peptide for the recurrence of atrial fibrillation six months after external cardioversion. 54 61
19155659 2008
A novel SCN5A gain-of-function mutation M1875T associated with familial atrial fibrillation. 61 54
18929244 2008
[Influence of electrical cardioversion on troponine I and brain natriuretic peptide (NT-proBNP) levels in patients with persistent atrial fibrillation/flutter]. 54 61
18979903 2008
[The incidence and predictors of atrial fibrillation in hypertrophic cardiomyopathy]. 54 61
19040064 2008
[Comparison of peripheral blood hematopoietic progenitor cells among patients with paroxysmal, permanent atrial fibrillation or sinus rhythm]. 61 54
19100027 2008
ACE inhibitors as antifibrotic agents in atrial fibrillation: potential relevance in cardiac surgery. 61 54
18495720 2008
N-terminal pro B-type natriuretic peptide levels predict newly detected atrial fibrillation in a population-based cohort. 61 54
18345329 2008
Association of Met439Thr substitution in heat shock protein 70 gene with postoperative atrial fibrillation and serum HSP70 protein levels. 54 61
17934269 2008
Natriuretic peptides in patients with atrial fibrillation. 54 61
19039756 2008
KCNQ1 mutation Q147R is associated with atrial fibrillation and prolonged QT interval. 54 61
17997361 2007
Expanding spectrum of human RYR2-related disease: new electrocardiographic, structural, and genetic features. 54 61
17875969 2007
Effect of angiotensin-converting enzyme insertion/deletion genotype on collagen type I synthesis and degradation in patients with atrial fibrillation and arterial hypertension. 61 54
17927479 2007
[Effects of angiotensin converting enzyme inhibitor on the expression of angiotensin converting enzyme 2 in atrium of patients with atrial fibrillation]. 61 54
17961427 2007
Stretch-sensitive KCNQ1 mutation A link between genetic and environmental factors in the pathogenesis of atrial fibrillation? 54 61
17276182 2007
[Alternative approaches to treatment of paroxysmal atrial fibrillation]. 54 61
17561641 2007
MinK gene polymorphism in the pathogenesis of lone atrial fibrillation. 54 61
17165161 2006
Increased von Willebrand factor in acute stroke patients with atrial fibrillation. 61 54
17904039 2006
Effect of rate and rhythm control on left ventricular function and cardiac dimensions in patients with persistent atrial fibrillation: results from the RAte Control versus Electrical Cardioversion for Persistent Atrial Fibrillation (RACE) study. 61 54
15851259 2005
Association of the human minK gene 38G allele with atrial fibrillation: evidence of possible genetic control on the pathogenesis of atrial fibrillation. 61 54
12228786 2002
Atrial natriuretic peptide in patients with heart failure and chronic atrial fibrillation: role of duration of atrial fibrillation. 61 54
9489971 1998
Relationship between prothrombin activation fragment F1.2 and international normalized ratio in patients with atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators. 54 61
9183333 1997
Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. 61 54
1406859 1992
Design of a multicenter randomized trial for the Stroke Prevention in Atrial Fibrillation Study. The Stroke Prevention in Atrial Fibrillation Investigators. 61 54
2183405 1990
Inadequate oral anticoagulation with warfarin in women with cerebrovascular event and history of atrial fibrillation: the FibStroke study. 61
33475002 2021
Impact of multimorbidity and polypharmacy on the management of patients with atrial fibrillation: insights from the BALKAN-AF survey. 61
32700579 2021
Impact of Atrial Fibrillation on Acute Coronary Syndrome-Analysis of In-Hospital Outcomes and 30-Day Readmissions. 61
33385750 2021

Variations for Atrial Fibrillation

ClinVar genetic disease variations for Atrial Fibrillation:

6 (show all 44)
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 SCN5A NM_198056.2(SCN5A):c.4478A>G (p.Lys1493Arg) SNV Likely pathogenic 67898 rs199473260 3:38597211-38597211 3:38555720-38555720
2 SNTA1 NM_003098.2(SNTA1):c.1169C>T (p.Ala390Val) SNV Likely pathogenic 8476 rs121434500 20:31998009-31998009 20:33410203-33410203
3 SCN5A NM_000335.4(SCN5A):c.1282G>A (p.Glu428Lys) SNV Uncertain significance 30048 rs199473111 3:38647498-38647498 3:38606007-38606007
4 KCNJ2 NM_000891.2(KCNJ2):c.277G>A (p.Val93Ile) SNV Uncertain significance 30121 rs147750704 17:68171457-68171457 17:70175316-70175316
5 SCN5A NM_000335.5(SCN5A):c.5958C>A (p.Asn1986Lys) SNV Uncertain significance 30045 rs199473335 3:38591902-38591902 3:38550411-38550411
6 MYH7 NM_000257.4(MYH7):c.5190G>T (p.Met1730Ile) SNV Uncertain significance 617741 rs1566522989 14:23884683-23884683 14:23415474-23415474
7 TTN-AS1 NM_001267550.2(TTN):c.73391G>A (p.Arg24464Gln) SNV Uncertain significance 691684 rs750056949 2:179437468-179437468 2:178572741-178572741
8 TTN-AS1 NM_001267550.2(TTN):c.57399A>C (p.Leu19133Phe) SNV Uncertain significance 691692 rs1576219060 2:179462410-179462410 2:178597683-178597683
9 NUP155 NM_153485.3(NUP155):c.1348A>G (p.Met450Val) SNV Uncertain significance 977374 5:37333735-37333735 5:37333633-37333633
10 NEBL NM_006393.3(NEBL):c.1228-1338del Deletion Uncertain significance 977376 10:21131116-21131116 10:20842187-20842187
11 SCN5A NM_000335.4(SCN5A):c.414G>A (p.Met138Ile) SNV Uncertain significance 67865 rs199473060 3:38663959-38663959 3:38622468-38622468
12 HCN4 NM_005477.3(HCN4):c.2716G>A (p.Gly906Arg) SNV Uncertain significance 404123 rs373572497 15:73615718-73615718 15:73323377-73323377
13 TTN NM_001267550.2(TTN):c.4359A>T (p.Arg1453Ser) SNV Likely benign 47051 rs376857956 2:179642552-179642552 2:178777825-178777825
14 TTN-AS1 NM_001267550.2(TTN):c.63976C>T (p.His21326Tyr) SNV Likely benign 691743 rs1413306492 2:179451962-179451962 2:178587235-178587235
15 TTN-AS1 NM_001267550.2(TTN):c.57356A>T (p.Lys19119Met) SNV Likely benign 691745 rs1576219870 2:179462453-179462453 2:178597726-178597726
16 TTN NM_001267550.2(TTN):c.44014G>A (p.Asp14672Asn) SNV Likely benign 691748 rs1339350914 2:179495761-179495761 2:178631034-178631034
17 TTN NM_001267550.2(TTN):c.42513T>A (p.His14171Gln) SNV Likely benign 691749 rs142842339 2:179498713-179498713 2:178633986-178633986
18 SCN5A NM_000335.5(SCN5A):c.5848G>T (p.Val1950Leu) SNV Likely benign 36765 rs41315493 3:38592012-38592012 3:38550521-38550521
19 TTN-AS1 NM_001267550.2(TTN):c.101212C>T (p.Arg33738Cys) SNV Likely benign 47633 rs56273463 2:179400130-179400130 2:178535403-178535403
20 TTN-AS1 NM_001267550.2(TTN):c.69130C>T (p.Pro23044Ser) SNV Likely benign 47265 rs55980498 2:179441932-179441932 2:178577205-178577205
21 TTN-AS1 NM_001267550.2(TTN):c.47315G>A (p.Arg15772Gln) SNV Benign 47010 rs72677233 2:179482763-179482763 2:178618036-178618036
22 TTN NM_001267550.2(TTN):c.18776C>G (p.Thr6259Ser) SNV Benign 46644 rs72648949 2:179594107-179594107 2:178729380-178729380
23 TTN NM_001267550.2(TTN):c.9359G>A (p.Arg3120Gln) SNV Benign 47636 rs72647894 2:179632598-179632598 2:178767871-178767871
24 KCNH2 NM_000238.4(KCNH2):c.2690A>C (p.Lys897Thr) SNV Benign 67427 rs1805123 7:150645534-150645534 7:150948446-150948446
25 BAG3 NM_004281.4(BAG3):c.187C>G (p.Pro63Ala) SNV Benign 178006 rs144041999 10:121429369-121429369 10:119669857-119669857
26 BAG3 NM_004281.4(BAG3):c.1138C>T (p.Pro380Ser) SNV Benign 162782 rs144692954 10:121436204-121436204 10:119676692-119676692
27 HCN4 NM_005477.3(HCN4):c.2648C>G (p.Pro883Arg) SNV Benign 137542 rs148398509 15:73615786-73615786 15:73323445-73323445
28 TTN-AS1 NM_001267550.2(TTN):c.87877C>T (p.Arg29293Cys) SNV Benign 47470 rs191482653 2:179422112-179422112 2:178557385-178557385
29 TTN NM_001267550.2(TTN):c.8902+14T>A SNV Benign 137827 rs13388274 2:179634392-179634392 2:178769665-178769665
30 ANK2 NM_001148.6(ANK2):c.9854T>C (p.Ile3285Thr) SNV Benign 190528 rs36210417 4:114279628-114279628 4:113358472-113358472
31 AKAP9 NM_005751.4(AKAP9):c.139C>T (p.His47Tyr) SNV Benign 191549 rs35669569 7:91603115-91603115 7:91973801-91973801
32 SCN5A NM_000335.4(SCN5A):c.1410C>G (p.Asn470Lys) SNV not provided 30047 rs199473115 3:38646328-38646328 3:38604837-38604837
33 KCNE2 NM_172201.1(KCNE2):c.269A>G (p.Glu90Gly) SNV not provided 67617 rs199473366 21:35743046-35743046 21:34370747-34370747
34 KCNQ1 NM_181798.1(KCNQ1):c.59A>G (p.Gln20Arg) SNV not provided 67074 rs199472689 11:2549211-2549211 11:2527981-2527981
35 SCN5A NM_198056.2(SCN5A):c.5624T>C (p.Met1875Thr) SNV not provided 68002 rs199473324 3:38592239-38592239 3:38550748-38550748
36 KCNQ1 NM_181798.1(KCNQ1):c.37A>G (p.Ser13Gly) SNV not provided 3143 rs120074192 11:2549189-2549189 11:2527959-2527959
37 KCNQ1 NM_181798.1(KCNQ1):c.40G>A (p.Val14Met) SNV not provided 67072 rs199472687 11:2549192-2549192 11:2527962-2527962
38 KCNQ1 NM_181798.1(KCNQ1):c.244T>C (p.Ser82Pro) SNV not provided 67094 rs199472705 11:2592575-2592575 11:2571345-2571345
39 KCNE2 NM_172201.1(KCNE2):c.79C>T (p.Arg27Cys) SNV not provided 6055 rs74315449 21:35742856-35742856 21:34370557-34370557
40 SCN5A NM_198056.2(SCN5A):c.1333C>G (p.His445Asp) SNV not provided 30046 rs199473112 3:38647447-38647447 3:38605956-38605956
41 SCN5A NM_198056.2(SCN5A):c.1963G>A (p.Glu655Lys) SNV not provided 30049 rs199473579 3:38640469-38640469 3:38598978-38598978
42 SCN5A NM_198056.2(SCN5A):c.3392C>T (p.Thr1131Ile) SNV not provided 67795 rs199473197 3:38618271-38618271 3:38576780-38576780
43 SCN5A NM_198056.2(SCN5A):c.5476C>T (p.Arg1826Cys) SNV not provided 67994 rs199473635 3:38592387-38592387 3:38550896-38550896
44 SCN5A NM_198056.2(SCN5A):c.5851G>A (p.Val1951Met) SNV not provided 68014 rs41315493 3:38592012-38592012 3:38550521-38550521

Expression for Atrial Fibrillation

Search GEO for disease gene expression data for Atrial Fibrillation.

Pathways for Atrial Fibrillation

Pathways related to Atrial Fibrillation according to KEGG:

# Name Kegg Source Accession
1 Vascular smooth muscle contraction hsa04270
2 Adrenergic signaling in cardiomyocytes hsa04261

Pathways related to Atrial Fibrillation according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
13 10.91 KCNQ1 KCNJ2 HCN4
14 10.88 NPPB NPPA

GO Terms for Atrial Fibrillation

Cellular components related to Atrial Fibrillation according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 10.31 SNTA1 SCN5A SCN4B SCN3B SCN2B SCN1B
2 integral component of membrane GO:0016021 10.27 SCN5A SCN4B SCN3B SCN2B SCN1B KCNQ1
3 plasma membrane GO:0005886 10.17 SNTA1 SCN5A SCN4B SCN3B